PDCD1 and cancer: Using CRISPR/Cas9 technology to knock out immune checkpoints such as programmed death-1 (PD-1), programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) may provide a new direction for cancer immunotherapy (15).